Sobi publishes its Report for the Third Quarter 2015 - Seite 2
About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease
products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics
manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at
www.sobi.com.
For more information please contact
Media relations | Investor relations |
Oskar Bosson, Head of Communications | Jörgen Winroth, Vice President, Head of Investor Relations |
T: +46 70 410 71 80 | T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
oskar.bosson@sobi.com | jorgen.winroth@sobi.com |
Lesen Sie auch
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire